DBS of the MLR for Gait and Balance Disorders in PD Patients
DBS of the MLR for Gait and Balance Disorders in PD Patients
Gait and balance disorders represent the main motor disability in advanced Parkinson's
 disease. These symptoms are less or unresponsive to levodopa treatment and are considered to
 be a contraindication for deep brain stimulation of the subthalamic nucleus. Falls and
 freezing of gait are responsible for high morbidity (fractures, residential health care) and
 increased significantly mortality. The pathophysiology of gait and balance disorders is still
 poorly understood, but recent data obtained in animals and humans suggest that a degeneration
 of cholinergic neurons of the pedunculopontine nucleus (PPN), within the mesencephalic
 locomotor region, could play a crucial role. In line with this hypothesis, low-frequency
 stimulation of the pedunculopontine area, thought to increase the activity of the remaining
 cholinergic PPN neurons, has been proposed to alleviate gait and balance disorders in
 advanced PD patients. Here, the efficacy of deep brain stimulation of the mesencephalic
 locomotor region will be tested in 12 PD patients in a randomized, double-blind, cross-over,
 controlled study.
Inclusion Criteria:

 -  age below 71 years

 -  severe form of Parkinson's Disease with disease duration > 5 years

 -  presence of gait and/or balance disorders unresponsive to levodopa treatment,

 -  > 40% decrease in others motor symptoms with levodopa treatment

 -  health insurance

 -  give signed informed written consent

 Exclusion Criteria:

 -  dementia (Mattis Dementia Rating Scale < 129, MDRS),

 -  ongoing psychiatric disturbances,

 -  surgical contraindications

 -  significant brain lesions detected on MRI.